VANDA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.62 USD | +3.12% |
|
-9.59% | +9.48% |
| Apr. 25 | Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer | RE |
| Apr. 22 | Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,371 | 875.3 | 718.6 | 874.1 | 418.2 | 242.8 |
| Enterprise Value (EV) 1 | 1,113 | 577.7 | 364.5 | 453.7 | -37.52 | -136.1 |
| P/E ratio | 54.4 x | 7.78 x | 31.3 x | 27.1 x | 67.2 x | 106 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 7.1 x | 3.85 x | 2.9 x | 3.25 x | 1.64 x | 1.26 x |
| EV / Revenue | 5.76 x | 2.54 x | 1.47 x | 1.69 x | -0.15 x | -0.71 x |
| EV / EBITDA | 45.1 x | 22.5 x | 12.1 x | 10.1 x | -4.14 x | 12.4 x |
| EV / FCF | -37.3 x | 17.1 x | 9.46 x | 9.41 x | -1.16 x | 1.53 x |
| FCF Yield | -2.68% | 5.83% | 10.6% | 10.6% | -86.2% | 65.2% |
| Price to Book | 4.98 x | 2.14 x | 1.59 x | 1.74 x | 0.8 x | 0.45 x |
| Nbr of stocks (in thousands) | 52,450 | 53,337 | 54,692 | 55,712 | 56,590 | 57,532 |
| Reference price 2 | 26.13 | 16.41 | 13.14 | 15.69 | 7.390 | 4.220 |
| Announcement Date | 2/19/19 | 2/26/20 | 2/11/21 | 2/24/22 | 2/9/23 | 2/8/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 193.1 | 227.2 | 248.2 | 268.7 | 254.4 | 192.6 |
| EBITDA 1 | 24.69 | 25.7 | 30.1 | 45.01 | 9.062 | -10.94 |
| EBIT 1 | 21.74 | 22.81 | 27.24 | 42.16 | 6.329 | -13.95 |
| Operating Margin | 11.26% | 10.04% | 10.98% | 15.69% | 2.49% | -7.24% |
| Earnings before Tax (EBT) 1 | 25.35 | 29.03 | 31.66 | 42.36 | 11.3 | 6.339 |
| Net income 1 | 25.21 | 115.6 | 23.34 | 33.15 | 6.275 | 2.509 |
| Net margin | 13.05% | 50.86% | 9.4% | 12.34% | 2.47% | 1.3% |
| EPS 2 | 0.4800 | 2.110 | 0.4200 | 0.5800 | 0.1100 | 0.0400 |
| Free Cash Flow 1 | -29.84 | 33.7 | 38.52 | 48.22 | 32.34 | -88.78 |
| FCF margin | -15.45% | 14.83% | 15.52% | 17.95% | 12.71% | -46.08% |
| FCF Conversion (EBITDA) | - | 131.1% | 127.95% | 107.15% | 356.91% | - |
| FCF Conversion (Net income) | - | 29.16% | 165.04% | 145.46% | 515.44% | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/19/19 | 2/26/20 | 2/11/21 | 2/24/22 | 2/9/23 | 2/8/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 70.1 | 68.02 | 60.19 | 64.39 | 65.32 | 64.48 | 46.06 | 38.82 | 45.27 |
| EBITDA | 15.48 | 9.342 | - | - | - | - | - | - | - |
| EBIT 1 | 10.82 | 8.636 | -7.669 | 3.461 | 3.908 | 6.629 | -2.867 | -5.995 | -7.094 |
| Operating Margin | 15.43% | 12.7% | -12.74% | 5.38% | 5.98% | 10.28% | -6.23% | -15.45% | -15.67% |
| Earnings before Tax (EBT) 1 | 10.72 | 8.61 | -7.564 | 3.79 | 5.461 | 9.613 | 2.592 | -0.12 | -1.661 |
| Net income 1 | 7.771 | 7.078 | -6.43 | 2.574 | 3.27 | 6.861 | 1.52 | 0.137 | -2.4 |
| Net margin | 11.09% | 10.41% | -10.68% | 4% | 5.01% | 10.64% | 3.3% | 0.35% | -5.3% |
| EPS 2 | 0.1400 | 0.1200 | -0.1100 | 0.0500 | 0.0600 | 0.1200 | 0.0300 | - | -0.0400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/23/22 | 5/5/22 | 8/3/22 | 11/2/22 | 2/8/23 | 7/27/23 | 11/8/23 | 2/7/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 257 | 298 | 354 | 420 | 456 | 379 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -29.8 | 33.7 | 38.5 | 48.2 | 32.3 | -88.8 |
| ROE (net income / shareholders' equity) | 12.4% | 33.7% | 5.4% | 6.92% | 1.22% | 0.47% |
| ROA (Net income/ Total Assets) | 5.05% | 3.49% | 3.35% | 4.68% | 0.64% | -1.36% |
| Assets 1 | 498.7 | 3,307 | 697.2 | 709 | 974.1 | -184.5 |
| Book Value Per Share 2 | 5.250 | 7.670 | 8.260 | 9.030 | 9.280 | 9.470 |
| Cash Flow per Share 2 | 1.160 | 0.8400 | 1.110 | 0.9300 | 2.380 | 2.360 |
| Capex 1 | 0.37 | 1.02 | 1.8 | 0.55 | 0.68 | 101 |
| Capex / Sales | 0.19% | 0.45% | 0.72% | 0.21% | 0.27% | 52.45% |
| Announcement Date | 2/19/19 | 2/26/20 | 2/11/21 | 2/24/22 | 2/9/23 | 2/8/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +9.48% | 266M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- VNDA Stock
- Financials Vanda Pharmaceuticals Inc.
